亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

HIV Gene Therapy Treatment

技术优势: Potential to cure infected patients without the need of ongoing treatments or the use of expensive laboratory or clinical equipmentCould be made accessible to doctors and patients without specialized facilities, particularly those in developing countries where HIV infection is widespread

详细技术说明: Currently, HIV patients must undergo chronic drug treatments and often suffer adverse side effects to manage their disease. Researchers at the University of California, Davis have developed a novel HIV gene therapy that specifically targets those cells in a patient that are susceptible to infection. Current methods of HIV gene therapy require the removal and isolation of specific cells from the patient, introduction of the therapeutic vector into the cells, and administration of these cells back into the patient. This new technology would allow the introduction of the vector directly into the patient without the need of removing and isolating cells in a laboratory or clinic. Another significant advantage of this HIV gene therapy is its potential to actually cure the disease. The standard treatment for HIV patients consists of a small molecule drug cocktail that must be taken throughout the patient's life to inhibit the replication of the virus. With the proposed therapy, anti-HIV genes are integrated into the target cells' genomes rendering them immune to infection. If enough target cells are successfully treated, the patient could potentially be cured of the infection. The HIV gene therapy uses recognition of an HIV receptor on the surface of host cells to identify which cells are susceptible to infection. Once recognized, these target cells are transduced with anti-HIV genes that prevent the replication and transmission of the virus.

*Abstract: Delivery of gene therapy with a targeting vector specific for cells susceptible to HIV infection.

*Principal Investigation: Name: Joseph Anderson
Department:

Name: Gerhard Bauer
Department:

附加资料: Patent Number: US8728458B2
Application Number: US13266236A
Inventor: Anderson, Joseph | Bauer, Gerhard | Nolta, Jan A.
Priority Date: 30 Apr 2009
Priority Number: US8728458B2
Application Date: 2 Dec 2011
Publication Date: 20 May 2014
IPC Current: A61K004800
US Class: 42409321 | 4353201 | 435325 | 514044A | 43532001 | 514044
Assignee Applicant: The Regents of the University of California
Title: Combination anti-HIV vectors, targeting vectors, and methods of use
Usefulness: Combination anti-HIV vectors, targeting vectors, and methods of use
Summary: The lentiviral vector, the pseudotyped lentiviral vector particle, or the cell is useful for treating an HIV infection in a subject or for manufacturing a medicament to treat an HIV infection in a subject (all claimed).
Novelty: New lentiviral vector comprises a lentiviral backbone and a nucleic acid encoding CCR5 RNA interference, tripartite motif-containing 5 alpha sequence, and HIV trans-activating response region sequence, useful for treating HIV infection

其他

Related Materials

Related Technologies

Additional Technologies by these Inventors

Tech ID/UC Case

19392/2009-477-0

Related Cases

2009-477-0

欲了解更多信息，请点击这里